- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05994365
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
A Real-world Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ming Gao, PhD
- Phone Number: + 86 18622221110
- Email: gaoming68@aliyun.com
Study Contact Backup
- Name: Yansong Lin, PhD
- Phone Number: +86 13671116837
- Email: linys@pumch.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100007
- Recruiting
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Yansong Lin, PhD
- Phone Number: +86 13671116837
- Email: linys@pumch.cn
-
-
Tianjin
-
Tianjin, Tianjin, China, 300122
- Recruiting
- Tianjin People's Hospital
-
Contact:
- Ming Gao, PhD
- Phone Number: + 86 18622221110
- Email: gaoming68@aliyun.com
-
Tianjin, Tianjin, China, 300181
- Recruiting
- Tianjin Cancer Hospital
-
Contact:
- Xiangqian Zheng, PhD
- Phone Number: +86 18622220506
- Email: xiangqian_zheng@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients voluntarily participate in this study, sign the informed consent form and had good compliance;
- Aged 18 ~ 70 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0~1; more than 6 months of expected survival ;
- Histopathologically confirmed locally advanced or metastatic differentiated thyroid cancer, radiographically documented disease progression within 18 months of absence of radioactive iodine (RAI) therapy;
Meet any of the following:
Lesions were not iodine-avid: no RAI uptake was confirmed after RAI scan in the presence of a low-iodine diet, adequate thyroid stimulating hormone (TSH) elevation (≥ 30 mIU/L). The definition of no iodine uptake:
- no iodine uptake initially;
- exist of iodine uptake initially while lost subsequently;
- partially uptake;
- progression disease despite iodine uptake.
- The cumulative dose of RAI was ≥ 600 mCi or 22 GBq, with an interval of at least 3 months.
- Radiographically documented disease progression within 18 months of RAI therapy despite the presence of iodine-131 affinity at the time of RAI therapy;
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.
Major organ functions meet the following criteria within 7 days prior to treatment:
Blood routine test criteria (14 days without blood transfusion):
- Hemoglobin (HB) ≥ 85 g/L;
- Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L;
- Platelet (PLT) ≥ 80 × 10^9/L
Biochemical tests need to meet the following criteria:
- Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN);
- Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2 .5×ULN, ALT and AS if liver metastases T ≤ 5 ×ULN;
- Serum creatinine (Cr) ≤ 1 .5 ×ULN or creatinine clearance (CCr) ≥ 60 Ml/min;
- Females of childbearing potential should agree to use contraceptive measures (such as intrauterine device, contraceptives or condoms) during the study and within 6 months after the end of the study; have a negative serum or urine pregnancy test within 7 days before study enrollment and must be non-lactating patients; and males should agree to use contraceptive measures during the study and within 6 months after the end of the study period.
Exclusion Criteria:
Comorbidities and medical history:
- A history of or concurrent with other malignancies within the past 3 years. Patients were eligible if they had disease-free survival (DFS) for 5 consecutive years in other malignancies treated by single surgery; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
- Major surgical treatment, open biopsy, or significant traumatic injury within 28 days before the start of study treatment;
Subjects with any severe and/or uncontrolled illness, including:
- Patients with ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (including Corrected QT Interval (QTc)≥450ms(male), QTc≥ 470ms(female)) and ≥ grade 2 congestive heart failure (NYHA classification);
- Severe active or uncontrolled infection (≥ grade 2 infection according to Common Terminology Criteria for Adverse Events (CTCAE) );
- Renal failure requiring hemodialysis or peritoneal dialysis;
- Patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study, or patients who are considered to be unsuitable for enrollment for other reasons according to the judgment of the investigators.
- patients with previous treatment with anlotinib hydrochloride capsules or similar vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) small molecule drugs, such as vandetanib, Cabozantinib, lenvatinib, sunitinib, or sorafenib, etc.;
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Anlotinib group
Anlotinib hydrochloride capsules: 12 mg once daily for 2 weeks, followed by a discontinuation of 1 week (21 days as a cycle)
|
Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
|
Observation group
Observation: prospectively and retrospectively collect data of patients who did not receive anlotinib hydrochloride capsules or similar small-molecule antivascular inhibitors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Baseline up to 3 years.
|
The proportion of subjects who achieves a best overall response of complete response (CR) or partial response (PR).
|
Baseline up to 3 years.
|
Progression-free Survival (PFS)
Time Frame: Baseline up to 3 years.
|
From the first dose to the date of objective disease progression or death, whichever occurs first.
|
Baseline up to 3 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse event rate
Time Frame: Baseline up to 3 years.
|
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
|
Baseline up to 3 years.
|
Disease-control Rate (DCR)
Time Frame: Baseline up to 3 years.
|
The proportion of subjects response of CR, PR, or stable disease (SD), subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks.
|
Baseline up to 3 years.
|
Duration of Response (DOR)
Time Frame: Baseline up to 3 years.
|
From the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first.
|
Baseline up to 3 years.
|
Overall Survival (OS)
Time Frame: Baseline up to 3 years.
|
From randomization to the time of death from any cause.
|
Baseline up to 3 years.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A LOT-DTC-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Neoplasms
-
Aarhus University HospitalOdense University Hospital; University of AarhusEnrolling by invitationThyroid Cancer | Thyroid Nodule (Diagnosis)Denmark
-
Wuhan UniversityRecruitingThyroid Carcinoma | Thyroid Nodule (Benign) | Ablation; RetinaChina
-
Rigen BiotechRenJi Hospital; Tianjin Medical University Cancer Institute and Hospital; Guangdong... and other collaboratorsRecruitingThyroid Cancer | Thyroid NoduleChina
-
University of FloridaNational Cancer Institute (NCI)RecruitingThyroid Cancer | Thyroid NodulesUnited States
-
Inha University HospitalRecruitingThyroid Cancer | Thyroid NoduleKorea, Republic of
-
Shanghai 10th People's HospitalUnknown
-
Boston Medical CenterCompletedThyroid Neoplasms | Thyroid Cancer | Thyroid NoduleUnited States
-
Pulse Biosciences, Inc.RecruitingThyroid Nodule (Benign)Italy
-
University of CagliariRecruitingIndeterminate Thyroid NodulesItaly
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingThyroid Gland CarcinomaUnited States
Clinical Trials on Anlotinib Hydrochloride Capsule
-
Peking Union Medical College HospitalNot yet recruitingLocally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid CarcinomaChina
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMedullary Thyroid CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Shandong Cancer Hospital and InstituteTerminatedNon-small Cell Lung CancerChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedNon-small Cell Lung CancerChina